Dr. Jed G. Nuchtern leads a collaborative research program that includes translational and clinical research on developing new treatments for pediatric solid tumors, particularly neuroblastoma. The primary focus in his laboratory is identifying new targets for neuroblastoma therapy. Bioinformatic studies have identified several proteins whose expression is increased in high-risk neuroblastoma tumors. The laboratory has validated these findings and demonstrated that blocking the expression of these target proteins decreases tumor growth and progression. Current research seeks to identify the pathways through which these molecules affect tumor progression.
In addition to these translational studies, Dr. Nuchtern is involved in clinical research on neuroblastoma in infants. Through the Children’s Oncology Group, he designed and implemented a prospective international study investigating the safety and efficacy of expectant observation as the primary treatment modality for infants with low risk adrenal tumors.